Biotechs As In-Licensers
Executive Summary
A closer look at the trend in biotech (top tier, and others) and specialty pharma in-licensing of clinical stage products.
You may also be interested in...
Increased Competition for Big Pharma in Late-Stage Licensing?
Do in-licensing-focused specialty pharmas spell tougher competition for Big Pharma, traditionally the biggest customer for late-stage product licenses?
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.